| 08:30 | P980 | Small tolerated enalapril doses before ARNI administration predicts adverse events during ARNI up-titration | Argyrios NTALIANIS (Athens, Greece) |
|
| 08:30 | P981 | Prescription of sacubitril/valsartan in a real-world population | Joao AGOSTINHO (Lisboa, Portugal) |
|
| 08:30 | P982 | Use of sacubitril-valsartan in heart failure with reduced ejection fraction: real world experience | Fernanda Costa FERREIRA (Cascais- Estoril, Portugal) |
|
| 08:30 | P983 | The dangers of non-heart failure hospitalisation for heart failure patients: frequent medication changes without follow up | Ethel O'DONOGHUE (Dublin, Ireland) |
|
| 08:30 | P985 | Clinical, echocardiographic and cost improvement after the onset with sacubitril-valsartan in mexican patients with heart failure. | Veronica Vanesa GOMEZ LEIVA (Ciudad De Mexico, Mexico) |
|
| 08:30 | P987 | The efficacy of nicorandil for patients with ischemic chronic heart failure | Florina BATAR (Sibiu, Romania) |
|
| 08:30 | P988 | Sequential nephron blockade with diuretics improves diastolic dysfunction in patients with resistant hypertension | David FOUASSIER (Paris, France) |
|
| 08:30 | P989 | Optimising heart failure treatment following cardiac resynchronisation therapy | Kasper PRYDS (Aarhus N, Denmark) |
|
| 08:30 | P990 | Trimetazidine management: an extraordinary clinical response in patients with heart failure (TRIMEX-Study) | Eduardo Julian Jose CHUQUIURE (Mexico City, Mexico) |
|
| 08:30 | P991 | Careful volume assessment appears to be the critical factor in achieving clinical trial dose of sacubitril/valsartan in the community. | Maria FERRE-VALLVERDU (Valencia, Spain) |
|
| 08:30 | P992 | Cardiopulmonary exercise testing as a fundamental tool in the assessment of the functional class in treating sacubitril / valsartan. Results at 3 months | Cristina BELTRAN HERRERA (Madrid, Spain) |
|
| 08:30 | P993 | Safety profile of sacubitril-valsartan in heart failure with reduced ejection fraction with chronic kidney disease, a real life study | Alejandro RECIO MAYORAL (Seville, Spain) |
|
| 08:30 | P994 | Early left ventricular reverse remodeling after sacubitril-valsartan treatment. Subanalysis of SAVE-RLife study | Mario GALVAN RUIZ (Las Palmas De G. C., Spain) |
|
| 08:30 | P995 | Impacts of mineralocorticoid receptor antagonists on mortality in heart failure patients with beta-blockers | Naoko P KATO (Norrkoping, Sweden) |
|
| 08:30 | P996 | Response rate to sacubitril-valsartan in the community. Is there a clear phenotype? | Rebabonye PHARITHI (Dublin 16, Ireland) |
|
| 08:30 | P997 | Treatment of patients with heart failure with reduced ejection fraction (HFrEF) in Germany: differences between cardiologists and primary care physicans | Uwe ZEYMER (Ludwigshafen, Germany) |
|
| 08:30 | P998 | Effects of sacubitril/valsartan on cardiac performance and exercise capacity | Massimo MAPELLI (Milano, Italy) |
|
| 08:30 | P999 | Self-motivation, self-regulation and self-care in patients with heart failure: a sequential mixed-method study | Han Shi Jocelyn CHEW (Hong Kong, Hong Kong) |
|
| 08:30 | P1000 | Benefits of full yogic breathing for patients with chronic heart failure | Anna SHEVELYOK (Donetsk, Ukraine) |
|
| 08:30 | P1001 | Analysis of the effectiveness of health education imparted by nursing in an heart failure unit | Maria Del Carmen DURAN TORRALBA (Andujar, Spain) |
|
| 08:30 | P1002 | Comparative analysis of the European Heart Failure Self-Care Behavior Scale and the Self-care of Heart Failure Index in hospitalized patients with heart failure. | Ekaterina KARTAMYSCHEVA (Volgograd, Russian Federation) |
|
| 08:30 | P1003 | Utility of the implementation of a standardized evaluation program for therapeutic adherence in heart failure | Maria Del Carmen DURAN TORRALBA (Andujar, Spain) |
|
| 08:30 | P1004 | A propensity-matched study of moderate to severe obesity and mortality in heart failure | Pao-Hsien CHU (Taipei, Taiwan, Province of China) |
|
| 08:30 | P1006 | The influence of socio-clinical variables on the level of self-care in heart failure patients | Marta WLEKLIK (Wroclaw, Poland) |
|
| 08:30 | P1007 | Effects of time perspective and executive function on self-care in patients with heart failure: a cross-sectional study | Han Shi Jocelyn CHEW (Hong Kong, Hong Kong) |
|
| 08:30 | P1008 | Real world usage and outcomes of all HFrEF patients treated with sacubitril/valsartan in Belgium | Tahnee SENTE (Vilvoorde, Belgium) |
|
| 08:30 | P1009 | Sacubitril-valsartan and its effect on ventricular remodeling | Susana DEL PRADO DIAZ (Madrid, Spain) |
|
| 08:30 | P1010 | Short and medium-term safety and tolerability of Sacubitril-Valsartan and Empaglifozin joint intake | Herminio MORILLAS CLIMENT (Valencia, Spain) |
|
| 08:30 | P1011 | Angiotensin receptor-neprilysin inhibition improves peak oxygen consumption in reduced heart failure patients | Catia FERREIRA (Coimbra, Portugal) |
|
| 08:30 | P1012 | Sacubitril/Valsartan use in a real world experience: data from a large single-center population of heart failure patients with reduced ejection fraction | Massimo MAPELLI (Milano, Italy) |
|
| 08:30 | P1015 | Use of sacubitril-valsartan in elderly patients. Subanalysis of the SAVE-RLife study | Mario GALVAN RUIZ (Las Palmas De G. C., Spain) |
|
| 08:30 | P1016 | Allopurinol safety and efficacy in heart failure patients: a systematic review | Mohammad Mostafa ANSARI-RAMANDI (Tehran, Iran (Islamic Republic of)) |
|
| 08:30 | P1017 | Initial experience of a nursing consultation in the uptitration of neurohumoral treatment in patientes with heart failure and reduced ejection fraction | Vanessa ESCOLAR PEREZ (Balmaseda, Spain) |
|
| 08:30 | P1018 | The impact of the use of sacubitril/valsartan on clinical and echocardiographic parameters in heart failure patients | Abdallah ALMAGHRABY (Alexandria, Egypt) |
|
| 08:30 | P1019 | The efficacy of "Get With the Guidelines Heart Failure," a retrospective analysis | Perry FISHER (Astoria, United States of America) |
|
| 08:30 | P1020 | Echocardiographic assessment of treating patients with chronic heart failure with mid-range ejection fraction by external counterpulsation | Tofig JAHANGIROV (Baku, Azerbaijan) |
|
| 08:30 | P1021 | Early effects of Sacubitril/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction. | Giuseppe VITALE (Palermo, Italy) |
|
| 08:30 | P1022 | In-hospital management of disease modifying drugs in heart failure with reduced ejection fraction - an opportunity to improve? | Francisco ADRAGAO (Cascais, Portugal) |
|
| 08:30 | P1023 | Adherence to therapy in patients with chronic heart failure | Elena EFREMOVA (Ulyanovsk, Russian Federation) |
|
| 08:30 | P1024 | Hemodynamic and clinical effects of ARNI therapy in patients with advanced heart failure undergoing repeated Levosimendan infusions | |
|
| 08:30 | P1026 | Quality of heart failure treatment treated by residential cardiologists -The HeartFailureBavaria Project | Fabian BISENIUS (Essen, Germany) |
|
| 08:30 | P1027 | To evaluate the safety and tolerability of ARNI initiation in inpatient versus outpatient setting in an Asian population: a real world study | Yiliang ZHENG (Singapore, Singapore) |
|
| 08:30 | P1028 | The optimize-heart failure care program in our heart institute in Vietnam | Thi Nam Phuong DO (Ho Chi Minh, Viet Nam) |
|
| 08:30 | P1031 | Inpatient versus outpatient introduction of angiotensin receptor neprilysin inhibitor in chronic heart failure patients | Mehdi ALEYAN (Lyon, France) |
|
| 08:30 | P1032 | Management of patients with advanced heart failure and type 2 pulmonary hypertension. | Marketa HEGAROVA (Praha 4, Czechia) |
|
| 08:30 | P1033 | Neuroendocrine inhibition in patients with heart failure and severe aortic stenosis undergoing TAVI | Jesus E PINO MORENO (Atlantis, United States of America) |
|
| 08:30 | P1035 | Levosemindan using in pediatric patients with end-stage heart failure: single center experience. | Almira BAIGALKANOVA (Astana, Kazakhstan) |
|
| 08:30 | P1036 | Availability and accessibility to heart failure treatment in latin america | Stephania GALINDO (Cali, Colombia) |
|
| 08:30 | P1037 | Decongestion therapy: does it differ from discharge to usual life conditions and among heart failure patients? | Francisco ADRAGAO (Cascais, Portugal) |
|
| 08:30 | P1038 | The European Heart Failure self-care behaviour scale: psychometric testing of the Hebrew version | Tuvia BEN GAL (Ramat Hasharon, Israel) |
|